About: Viral RNA level, serum antibody responses, and transmission risk in discharged COVID-19 patients with recurrent positive SARS-CoV-2 RNA test results: a population-based observational cohort study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Viral RNA level, serum antibody responses, and transmission risk in discharged COVID-19 patients with recurrent positive SARS-CoV-2 RNA test results: a population-based observational cohort study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Viral RNA level, serum antibody responses, and transmission risk in discharged COVID-19 patients with recurrent positive SARS-CoV-2 RNA test results: a population-based observational cohort study
Creator	Liu, Hui Liu, Yingxia Yuan, Jing Yang, Ruifu Zhang, Huan Wang, Lei Li, Hao Jiang, Min Cui, Yujun Yang, Chao Liao, Xuejiao Wang, Xiaohui Feng, Tiejian Wan, Min Zheng, Huanying Zhang, Zhen Geng, Yijie Mei, Shujiang Mph, Tang, Xiujuan Xia, Junjie Zou, Xuan Fang, Shisong Li, Baisheng Hu, Qinghua Ren, Xiaohu Wu, Shuang Chen, Qiongcheng Jiang, Yixiang Lin, Yiman Lu, Linying Wu, Weihua Yang, Zhengrong Zheng, Chenli Zhong, Yifan Zuo, Le
Source	MedRxiv
abstract	Background Managing discharged COVID-19 (DC) patients with recurrent positive (RP) SARS-CoV-2 RNA test results is challenging. We aimed to comprehensively characterize the viral RNA level and serum antibody responses in RP-DC patients and evaluate their viral transmission risk. Methods A population-based observational cohort study was performed on 479 DC patients discharged from February 1 to May 5, 2020 in Shenzhen, China. We conducted RT-qPCR, antibody assays, neutralisation assays, virus isolation, whole genome sequencing (WGS), and epidemiological investigation of close contacts. Findings Of 479 DC patients, the 93 (19%) RP individuals, including 36 with multiple RP results, were characterised by young age (median age: 34 years, 95% confidence interval [CI]: 29-38 years). The median discharge-to-RP length was 8 days (95% CI: 7-14 days; maximum: 90 days). After readmission, RP-DC patients exhibited mild (28%) or absent (72%) symptoms, with no disease progression. The viral RNA level in RP-DC patients ranged from 1.9-5.7 log10 copies/mL (median: 3.2, 95% CI: 3.1-3.5). At RP detection, the IgM, IgG, IgA, total antibody, and neutralising antibody (NAb) seropositivity rates in RP-DC patients were 38% (18/48), 98% (47/48), 63% (30/48), 100% (48/48), and 91% (39/43), respectively. Regarding antibody levels, there was no significant difference between RP-DC and non-RP-DC patients. The antibody level remained constant in RP-DC patients pre- and post-RP detection. Virus isolation of nine representative specimens returned negative results. WGS of six specimens yielded only genomic fragments. No clinical symptoms were exhibited by 96 close contacts of 23 RP-DC patients; their viral RNA (96/96) and antibody (20/20) test results were negative. After full recovery, 60% of patients (n=162, 78 no longer RP RP-DC and 84 non-RP-DC) had NAb titres of [≥]1:32. Interpretation RP may occur in DC patients following intermittent and non-stable excretion of low viral RNA levels. RP-DC patients pose a low risk of transmitting SARS-CoV-2. An NAb titre of [≥]1:32 may provide a reference indicator for evaluating humoral responses in COVID-19 vaccine clinical trials.
has issue date	2020-07-26(xsd:dateTime)
bibo:doi	10.1101/2020.07.21.20125138
has license	medrxiv
sha1sum (hex)	36f9a09ff8f4fa3376933cca672fb25c2d1657d0
schema:url	https://doi.org/10.1101/2020.07.21.20125138
resource representing a document's title	Viral RNA level, serum antibody responses, and transmission risk in discharged COVID-19 patients with recurrent positive SARS-CoV-2 RNA test results: a population-based observational cohort study
resource representing a document's body	covid:36f9a09ff8f4fa3376933cca672fb25c2d1657d0#body_text
is schema:about of	named entity 'February' named entity 'serum' named entity 'patients' named entity 'Methods' named entity 'Viral' named entity 'transmission' named entity 'THEIR' named entity 'RT-QPCR' named entity 'RESULTS' named entity 'BACKGROUND' named entity 'test' named entity 'observational' named entity 'China' named entity 'discharged' named entity 'risk' named entity 'antibody' named entity 'WGS' named entity 'antibody' named entity 'serum' named entity 'Viral' named entity 'evaluate' named entity 'antibody' named entity 'NAb' named entity 'CDC' named entity 'medRxiv' named entity 'false-negative' named entity 'medRxiv' named entity 'copyright holder' named entity 'preprint' named entity 'methylprednisolone' named entity 'preprint' named entity 'cellular immunity' named entity 'SARS-CoV-2' named entity 'medRxiv' named entity 'preprint' named entity 'CC-BY-NC-ND 4.0' named entity 'report writing' named entity 'p<0.05' named entity 'clinical samples' named entity 'dexamethasone' named entity 'antibody' named entity 'preprint' named entity 'copyright holder' named entity 'preprint' named entity 'IgG' named entity 'preprint' named entity 'significant difference' named entity 'preprint' named entity 'preprint' named entity 'SARS-CoV-2'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software